Filing Flows

Filing Flows › Companies › Ensysce Biosciences › Cash flow

Ensysce Biosciences cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$2.0M in Q2 2026 · −$8.9M over twelve months

Operating cash flow−$2.0M
Free cash flow−$2.0M

Analysis

In Q2 2026, Ensysce Biosciences generated −$2.0M of operating cash flow. That is $744K more than in Q2 2025 (−$2.7M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$8.9M; the largest uses were operating cash flow ($8.9M); besides operations, cash came from other financing ($7.4M); the cash balance fell by $1.5M.

Operating cash flow was −$2.0M against net income of −$2.6M. The largest differences: accrued liabilities +$313K, payables +$308K, depreciation & amortization +$7K.

Free cash flow

Ensysce Biosciences: free cash flow by quarterEnsysce Biosciences: free cash flow by quarter−$1.0MQ3 2024−$764KQ4 2024−$1.7MQ1 2025−$2.7MQ2 2025−$1.9MQ3 2025−$1.5MQ4 2025−$3.5MQ1 2026−$2.0MQ2 2026
Operating cash flow less capital spending.
Ensysce Biosciences: operating cash flow against capital spendingEnsysce Biosciences: operating cash flow against capital spendingOperating cash flowCapital spending−$1.0M$0Q3 2024−$764K$0Q4 2024−$1.7M$0Q1 2025−$2.7M$0Q2 2025−$1.9M$0Q3 2025−$1.5M$0Q4 2025−$3.5M$0Q1 2026−$2.0M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$2.0M, Capital spending $0.

Capital allocation, year by year

Ensysce Biosciences: where the cash came from (up) and went (down), by fiscal yearEnsysce Biosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$8.2MFY2021: Net borrowing $14.0MFY2021: Shares issued $6.9M$20.9MFY2021FY2022: Operating cash flow −$17.9MFY2022: Net borrowing $6.1MFY2022: Shares issued $3.8MFY2022: Asset sales $4K$9.9MFY2022FY2023: Operating cash flow −$10.8MFY2023: Net borrowing $605KFY2023: Shares issued $9.1M$9.7MFY2023FY2024: Operating cash flow −$7.5MFY2024: Net borrowing −$485KFY2024: Shares issued $1.7M$1.7MFY2024FY2025: Operating cash flow −$7.8MFY2025: Shares issued $5.1MFY2025: Capital spending −$124K$5.1MFY2025
Over these 5 years operating cash flow totalled −$52.2M; the largest uses were operating cash flow ($52.2M) and net borrowing ($485K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$677K
Debtnone
Net cash$677K
Cash runway1 month

Ensysce Biosciences is burning cash: its operations consume cash, a free cash flow of −$8.9M a year at the current rate against $677K of cash and investments: a runway of about 1 month before any new financing.

Where the cash came from and went

Ensysce Biosciences: sources (+) and uses (−) of cash, Q2 2026Ensysce Biosciences: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$2.0MOther financing$1.9MCash drawn (+) / kept (−)$69K
Ensysce Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Ensysce Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$8.9MOther financing$7.4MCash drawn (+) / kept (−)$1.5MNot reconciled−$124K

From profit to cash

Ensysce Biosciences: net income to operating cash flow, Q2 2026Ensysce Biosciences: net income to operating cash flow, Q2 2026Net income−$2.6MDepreciation & amortization$7KStock-based pay$2KPayables$308KAccrued liabilities$313KOperating cash flow−$2.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$2.0M—$69K−$2.0M
Q1 2026−$3.5M—$3.6M−$3.5M
Q4 2025−$1.5M—−$2.6M−$1.5M
Q3 2025−$1.9M−$400K$538K−$1.9M
Q2 2025−$2.7M$1$841K−$2.7M
Q1 2025−$1.7M$1.1M$450K−$1.7M
Q4 2024−$764K—$652K−$764K
Q3 2024−$1.0M—−$3.1M−$1.0M

Ensysce Biosciences: income statement and cash flow

Ensysce Biosciences, Q2 2026: revenue $1.2M (-15% year over year), operating margin -221.3%. The chart follows the revenue to costs, profit and cash.

Ensysce Biosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.